Skip to main content

Table 3 Association between breast cancer median CXCL13 content and distant disease-fee survival in four molecular subtypes

From: Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population

Subtype Univariable modelHR (95% CI) P Multivariable modelHR (95% CI) P
Luminal A-like 0.60 (0.27–1.34) 0.214 0.57 (0.24–1.34) 0.194
Luminal B-like 0.59 (0.27–1.28) 0.180 0.49 (0.20–1.17) 0.109
Triple-negative 0.42 (0.22–0.83) 0.012 0.39 (0.19–0.79) 0.009
HER2-positive 0.78 (0.43–1.42) 0.421 0.75 (0.40–1.41) 0.372
  1. Abbreviations: CI confidence interval, HR hazard ratio, HER2 human epidermal growth factor receptor 2
\